CHCWM – Cancer & Hematology Centers of West Michigan

 (SKL27969C001) SK Life Sciences

Description: A phase 1, open-label, multicenter, dose-finding study of SKL27969 in patients with advanced solid tumors, central nervous system (CNS) tumors, and hematologic malignancies

Mechanism of Action:  PRMT5 Inhibitor.  MTAP deletions can be a biomarker of interest for this drug

Target Patient Population:  All solid tumors

Study Design:  Drug is given orally currently for 3 days on, 4 days off